BlackRock
KPTI icon

BlackRock’s Karyopharm Therapeutics KPTI Stock Holding History

BlackRock’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.36M Sell
244,899
-2,659
-1% -$20.3K ﹤0.01% 4240
2025
Q4 		$1.82M Buy
247,558
+15,607
+7% +$95.4K ﹤0.01% 4141
2025
Q3 		$1.52M Sell
231,951
-4,690
-2% -$25.2K ﹤0.01% 4180
2025
Q2 		$1.02M Sell
236,641
-6,101
-3% -$29.9K ﹤0.01% 4245
2025
Q1 		$908K Sell
242,742
-8,516
-3% -$72.7K ﹤0.01% 4222
2024
Q4 		$2.55M Buy
251,258
+8,699
+4% +$105K ﹤0.01% 3967
2024
Q3 		$3.02M Sell
242,559
-35,427
-13% -$440K ﹤0.01% 3872
2024
Q2 		$3.62M Sell
277,986
-351,859
-56% -$5.83M ﹤0.01% 3797
2024
Q1 		$14.3M Sell
629,845
-41,600
-6% -$729K ﹤0.01% 3170
2023
Q4 		$8.71M Sell
671,445
-67,657
-9% -$912K ﹤0.01% 3467
2023
Q3 		$14.9M Sell
739,102
-30,050
-4% -$674K ﹤0.01% 3105
2023
Q2 		$20.7M Buy
769,152
+164,339
+27% +$7.08M ﹤0.01% 3025
2023
Q1 		$35.3M Buy
604,813
+37,597
+7% +$1.86M ﹤0.01% 2670
2022
Q4 		$28.9M Buy
567,216
+39,686
+8% +$2.75M ﹤0.01% 2826
2022
Q3 		$43.2M Sell
527,530
-13,993
-3% -$1.05M ﹤0.01% 2551
2022
Q2 		$36.6M Buy
541,523
+13,015
+2% +$1.19M ﹤0.01% 2702
2022
Q1 		$58.4M Sell
528,508
-66,039
-11% -$8.23M ﹤0.01% 2494
2021
Q4 		$57.3M Buy
594,547
+8,526
+1% +$850K ﹤0.01% 2566
2021
Q3 		$51.2M Buy
586,021
+604
+0.1% +$62.7K ﹤0.01% 2648
2021
Q2 		$90.6M Buy
585,417
+68,767
+13% +$9.98M ﹤0.01% 2314
2021
Q1 		$81.5M Buy
516,650
+18,310
+4% +$3.86M ﹤0.01% 2304
2020
Q4 		$116M Buy
498,340
+20,354
+4% +$4.72M ﹤0.01% 1999
2020
Q3 		$105M Buy
477,986
+52,075
+12% +$12.7M ﹤0.01% 1852
2020
Q2 		$121M Buy
425,911
+70,844
+20% +$21M ﹤0.01% 1725
2020
Q1 		$102M Buy
355,067
+37,139
+12% +$10.2M 0.01% 1628
2019
Q4 		$91.4M Buy
317,928
+4,759
+2% +$1.03M ﹤0.01% 2023
2019
Q3 		$45.2M Buy
313,169
+11,402
+4% +$1.55M ﹤0.01% 2356
2019
Q2 		$27.1M Buy
301,767
+23,180
+8% +$1.86M ﹤0.01% 2675
2019
Q1 		$24.4M Sell
278,587
-5,274
-2% -$585K ﹤0.01% 2647
2018
Q4 		$39.9M Sell
283,861
-174
-0.1% -$29.4K ﹤0.01% 2367
2018
Q3 		$72.6M Buy
284,035
+13,659
+5% +$3.78M ﹤0.01% 2173
2018
Q2 		$68.9M Buy
270,376
+86,505
+47% +$21.4M ﹤0.01% 2169
2018
Q1 		$37M Buy
183,871
+7,928
+5% +$1.58M ﹤0.01% 2439
2017
Q4 		$25.3M Sell
175,943
-26,915
-13% -$4.32M ﹤0.01% 2663
2017
Q3 		$33.4M Buy
202,858
+5,528
+3% +$792K ﹤0.01% 2519
2017
Q2 		$26.8M Buy
197,330
+30,183
+18% +$4.47M ﹤0.01% 2629
2017
Q1 		$32.2M Buy
167,147
+166,870
+60,242% +$26.8M ﹤0.01% 2475
2016
Q4 		$39K Sell
277
-16
-5% -$2.16K ﹤0.01% 3045
2016
Q3 		$43K Sell
293
-140
-32% -$16.8K ﹤0.01% 3032
2016
Q2 		$44K Buy
433
+337
+351% +$43.8K ﹤0.01% 2996
2016
Q1 		$13K Sell
96
-73
-43% -$8.06K ﹤0.01% 3038
2015
Q4 		$34K Buy
169
+39
+30% +$8.45K ﹤0.01% 2268
2015
Q3 		$21K Buy
130
+89
+217% +$23.8K ﹤0.01% 2352
2015
Q2 		$17K Buy
41
+18
+78% +$7.78K ﹤0.01% 2475
2015
Q1 		$10K Sell
23
-5,534
-100% -$2.39M ﹤0.01% 2735
2014
Q4 		$3.12M Sell
5,557
-1,287
-19% -$731K ﹤0.01% 950
2014
Q3 		$3.59M Sell
6,844
-377
-5% -$213K 0.01% 917
2014
Q2 		$5.04M Buy
7,221
+1,931
+37% +$899K 0.01% 834
2014
Q1 		$2.45M Buy
5,290
+5,117
+2,958% +$2.59M ﹤0.01% 1008
2013
Q4 		$60K Buy
+173
New +$47.8K ﹤0.01% 1871

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

BlackRock's KPTI Position: Q1 2026 in Review

BlackRock reduced its Karyopharm Therapeutics (KPTI) stake by 1.1% in Q1 2026, selling an estimated $20.3K and leaving 244,899 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #4240.

BlackRock first reported a position in KPTI in Q4 2013 and has held it in 50 quarters since. The position peaked at $121M in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • BlackRock held 244,899 shares of Karyopharm Therapeutics worth $1.36M as of Q1 2026.
  • BlackRock sold 2,659 Karyopharm Therapeutics shares in Q1 2026, an estimated $20.3K.
  • Karyopharm Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4240 holding.
  • BlackRock first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • BlackRock's Karyopharm Therapeutics position peaked at $121M in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.